Telesis Bio Balance Sheet Health
Financial Health criteria checks 0/6
Insufficient data to determine the health of Telesis Bio
Key information
n/a
Debt to equity ratio
n/a
Debt
| Interest coverage ratio | n/a |
| Cash | n/a |
| Equity | n/a |
| Total liabilities | n/a |
| Total assets | n/a |
Recent financial health updates
Recent updates
In this section we usually analyse Telesis Bio's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Telesis Bio has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
Financial Position Analysis
Short Term Liabilities: Insufficient data to determine if TBIO's short term assets cover its short term liabilities.
Long Term Liabilities: Insufficient data to determine if TBIO's short term assets cover its long term liabilities.
Debt to Equity History and Analysis
Debt Level: Insufficient data to calculate TBIO's net debt to equity ratio to determine if it is satisfactory.
Reducing Debt: Insufficient data to determine if TBIO's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: Insufficient data to determine if TBIO's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if TBIO's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/23 12:23 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Telesis Bio, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brandon Couillard | Jefferies LLC |
| Paul Knight | KeyBanc Capital Markets Inc. |
| Douglas Schenkel | TD Cowen |